Physician profile
Sara Bashyam
NPI 1639583909
$5,661.53
in general payments reported to CMS, 2019-2025
33 companies · $2,451 in 2025
The $2,451 reported for 2025 was more than what 95% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $424 · 2022: $433 · 2023: $977 · 2024: $1,378 · 2025: $2,451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,804.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $372.02 | 2024-2025 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $370.21 | 2024-2025 | Breztri, Farxiga |
| Neurocrine Biosciences, INC. | $358.82 | 2023-2025 | Ingrezza |
| Novo Nordisk INC | $342.78 | 2024-2025 | Wegovy |
| Medtronic, INC. | $314.28 | 2025 | Symplicity G3, Micra |
| Gilead Sciences, INC. | $259.18 | 2025 | Livdelzi, Epclusa |
| Grifols USA, LLC | $251.63 | 2022-2024 | Prolastin-C Liquid |
| Teva Pharmaceuticals USA, INC. | $231.09 | 2024-2025 | Austedo Xr |
| Abiomed | $228.52 | 2025 | |
| Janssen Pharmaceuticals, INC | $219.90 | 2021-2024 | Xarelto |
| Amgen INC. | $218.27 | 2023-2025 | Repatha, Repatha |
| Genzyme Corporation | $190.66 | 2022-2025 | |
| Boston Scientific Corporation | $171.10 | 2023-2025 | Watchman Access System, Varithena Administration Pack |
| Edwards Lifesciences Corporation | $170.74 | 2025 | Sapien 3 Ultra Resilia |
| Baxter Healthcare | $146.17 | 2024 | Starling System |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nuwellis, INC. | $142.87 | 2021 | |
| Shield Therapeutics INC | $125.00 | 2023 | Accrufer |
| Actelion Pharmaceuticals US, INC. | $121.83 | 2025 | Opsumit, Uptravi |
| Sobi, INC | $120.18 | 2025 | |
| Idorsia Pharmaceuticals US INC | $118.81 | 2023 | Quviviq |
| Atricure, INC. | $117.35 | 2021 | |
| Axsome Therapeutics, INC. | $117.12 | 2025 | Auvelity |
| C. R. Bard, INC. & Subsidiaries | $116.45 | 2025 | Arctic Sun 5000 |
| Biogen, INC. | $107.28 | 2024 | |
| Novartis Pharmaceuticals Corporation | $106.37 | 2023 | |
| Genentech USA, INC. | $101.82 | 2023 | Evrysdi |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.10 | 2023 | Lifevest |
| Merck Sharp & Dohme LLC | $95.16 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.38 | 2025 | Jardiance |
| Grt US Holding, INC. | $88.55 | 2022 | |
| Abbott Laboratories | $78.86 | 2021-2024 | Amplatzer Amulet |
| Bayer Healthcare Pharmaceuticals INC. | $67.03 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Bashyam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.